All In Biotech

Free tool

FAERS Monitor: Jentadueto Xr

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208026 or its brand name (Jentadueto Xr, Linagliptin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

67

Serious

26

39% of reports

Hospitalization

12

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased7
  • weight decreased6
  • diarrhoea5
  • malaise4
  • pancreatitis4
  • tremor3
  • abdominal pain upper2
  • asthenia2
  • blood glucose abnormal2
  • confusional state2
  • death2
  • decreased appetite2
  • dental caries2
  • diabetes mellitus2
  • dizziness2

Reports by year received

View as table
YearReports
20173
201812
20195
202016
20214
20228
20234
20243
20257
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,092 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dental caries256.814.561
blood glucose abnormal234.08.735
pancreatitisSignal423.89.266
blood glucose increasedSignal711.75.859
diabetes mellitus28.22.17
weight decreasedSignal66.73.124
tremorSignal35.71.97
confusional state23.91.02
abdominal pain upper23.00.81
malaise42.91.13
decreased appetite22.70.71
diarrhoea52.41.03
asthenia21.70.40
dizziness21.30.30
death20.70.20

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.